AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19366848 — intervention group
Group type: EXPERIMENTAL
Intervention: T gel 10 g plus NES gel 6 mg
Number of subjects: 140
Study 19366848 — intervention group
Group type: EXPERIMENTAL
Intervention: T gel 10 g plus NES gel 8 mg
Number of subjects: 140
Study 18190254 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant EBV subunit glycoprotein 350 (gp350)/aluminum hydroxide and 3‐O‐desacyl‐4'‐monophosphoryl lipid A (AS04) candidate vaccine in a 3-dose regimen
Number of subjects: 181
Study 18190254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 15077888 — intervention group
Group type: EXPERIMENTAL
Intervention: Snoring prevalence
Number of subjects: 1252
Study 15077888 — intervention group
Group type: EXPERIMENTAL
Intervention: Snoring prevalence among males
Number of subjects: 1252
Study 15077888 — intervention group
Group type: EXPERIMENTAL
Intervention: Snoring prevalence among females
Number of subjects: 1252
Study 15077888 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related snoring prevalence
Number of subjects: 1252
Study 11480325 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium hypotonic oral rehydration solution (LSORS)
Number of subjects: 117
Study 11480325 — intervention group
Group type: COMPARATOR
Intervention: Standard WHO oral rehydration solution (STORS)
Number of subjects: 117
Study 9497194 — intervention group
Group type: EXPERIMENTAL
Intervention: gluten-free diet for 1 year
Number of subjects: 40
Study 9497194 — intervention group
Group type: COMPARATOR
Intervention: total villous atrophy
Number of subjects: 40
Study 7974683 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole with surgery (ABZ surgery group)
Number of subjects: 34
Study 7974683 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (non-ABZ surgery group)
Number of subjects: 34
Study 7974683 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole treatment alone (ABZ CE group)
Number of subjects: 34
Study 7974683 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole with surgical intervention (ABZ AE group)
Number of subjects: 34
Study 7974683 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole alone (ABZ AE group)
Number of subjects: 34
Study 2786292 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucovorin calcium 25 mg (formulation 1)
Number of subjects: 36
Study 2786292 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucovorin calcium 25 mg (formulation 2)
Number of subjects: 36
Study 5795804 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (10 mg, 20 mg, 40 mg)
Number of subjects: 1074
Study 5795804 — intervention group
Group type: COMPARATOR
Intervention: Morphine (5 mg, 10 mg)
Number of subjects: 1074
Study 31272682 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive respiratory rehabilitation (inspiratory training with an incentive spirometer, Coach 2®PORTEX) starting from day five postoperatively, performed four times a day and continued at home after discharge.
Number of subjects: 34
Study 31272682 — intervention group
Group type: COMPARATOR
Intervention: Control group (no respiratory rehabilitation).
Number of subjects: 34
Study 30903221 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-flexion (30°)
Number of subjects: 40
Study 30903221 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension (0°)
Number of subjects: 40
Study 27080998 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) of auricular acupressure, performed twice a week for 4 weeks at each acupoint for 30 seconds.
Number of subjects: 100
Study 27080998 — intervention group
Group type: COMPARATOR
Intervention: No electrical stimulation (no-ES) under auricular acupressure (control group).
Number of subjects: 100
Study 26002840 — intervention group
Group type: EXPERIMENTAL
Intervention: stavudine (d4T) switching to zidovudine (ZDV) at 24 weeks
Number of subjects: 150
Study 26002840 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine (ZDV)
Number of subjects: 150
Study 26002840 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir (TDF)
Number of subjects: 150
Study 26002840 — intervention group
Group type: EXPERIMENTAL
Intervention: All ART regimens combined with nevirapine
Number of subjects: 150
Study 23344779 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO measurement in children with AR
Number of subjects: 251
Study 23344779 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO measurement in children with combined AR and asthma
Number of subjects: 251
Study 23344779 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal assessment of FeNO and HDM-specific IgE
Number of subjects: 251
Study 21729167 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐estimated UV sensitivity according to Fitzpatrick's classification
Number of subjects: 166
Study 21729167 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual UV sensitivity measured by phototest
Number of subjects: 166
Study 19372329 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 4 ng/mL (Group R4)
Number of subjects: 100
Study 19372329 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 2 ng/mL (Group R2)
Number of subjects: 100
Study 19372329 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 3 ng/mL (Group R3)
Number of subjects: 100
Study 19372329 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 1 ng/mL (Group R1)
Number of subjects: 100
Study 16415283 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochloroacetic acid and 10% formaldehyde
Number of subjects: 57
Study 16415283 — intervention group
Group type: COMPARATOR
Intervention: 10% formaldehyde alone
Number of subjects: 57
Study 15499823 — intervention group
Group type: EXPERIMENTAL
Intervention: Children who were questioned about truth and lies and promised to tell the truth before the second interview.
Number of subjects: 201
Study 15499823 — intervention group
Group type: COMPARATOR
Intervention: Children who were questioned without prior discussion about truth and lies or a promise to tell the truth.
Number of subjects: 201
Study 15499823 — intervention group
Group type: EXPERIMENTAL
Intervention: Children in Experiment 1 when the likelihood of being blamed for the transgression was reduced.
Number of subjects: 201
Study 15499823 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's moral understanding of truth- and lie-telling assessed by a second interviewer.
Number of subjects: 201
Study 11672921 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent conjugate vaccine (conjugate-conjugate)
Number of subjects: 67
Study 11672921 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent conjugate vaccine followed by 23-valent polysaccharide vaccine (conjugate-polysaccharide)
Number of subjects: 67
Study 11672921 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo-polysaccharide)
Number of subjects: 67
Study 11672921 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo-placebo)
Number of subjects: 67
Study 9039508 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (4 mg/kg/day)
Number of subjects: 16
Study 9039508 — intervention group
Group type: COMPARATOR
Intervention: Supportive treatment
Number of subjects: 16
Study 8086602 — intervention group
Group type: EXPERIMENTAL
Intervention: Models for three-dimensional contingency tables
Number of subjects: 0
Study 8086602 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum likelihood methods
Number of subjects: 0
Study 8086602 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional goodness-of-fit test statistics
Number of subjects: 0
Study 3111615 — intervention group
Group type: EXPERIMENTAL
Intervention: Methenamine hippurate (1 g twice daily)
Number of subjects: 21
Study 3111615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31734702 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) training
Number of subjects: 381
Study 31734702 — intervention group
Group type: COMPARATOR
Intervention: Face-to-Face training
Number of subjects: 381
Study 29391310 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-3350+SD+B
Number of subjects: 150
Study 29391310 — intervention group
Group type: COMPARATOR
Intervention: PEG-AA
Number of subjects: 150
Study 27212005 — intervention group
Group type: COMPARATOR
Intervention: Axillary ultrasound (AUS) - no further axillary staging (arm 1)
Number of subjects: 68
Study 27212005 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB) - axillary staging (arm 2)
Number of subjects: 68
Study 23782595 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fluidic settings
Number of subjects: 57
Study 23782595 — intervention group
Group type: COMPARATOR
Intervention: High fluidic settings
Number of subjects: 57
Study 22302136 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly etanercept (OW) 25 mg
Number of subjects: 63
Study 22302136 — intervention group
Group type: COMPARATOR
Intervention: Twice-weekly etanercept (TW) 25 mg
Number of subjects: 63
Study 20201949 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cycles of CHOP followed by BEAM autograft
Number of subjects: 457
Study 20201949 — intervention group
Group type: COMPARATOR
Intervention: Continuing CHOP
Number of subjects: 457
Study 17577653 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month recall period
Number of subjects: 156
Study 17577653 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month rating task
Number of subjects: 156
Study 15881624 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine treatment (up to 600 mg/day)
Number of subjects: 38
Study 15881624 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine treatment
Number of subjects: 38
Study 12021647 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital CT scans showing optic nerve crowding
Number of subjects: 27
Study 12021647 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital CT scans showing intracranial fat prolapse
Number of subjects: 27
Study 12021647 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle index greater than 50%
Number of subjects: 27
Study 12021647 — intervention group
Group type: COMPARATOR
Intervention: Superior ophthalmic vein dilation
Number of subjects: 27
Study 12021647 — intervention group
Group type: COMPARATOR
Intervention: Proptosis
Number of subjects: 27
Study 10705056 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusidic acid 500 mg q8h orally for 7 days
Number of subjects: 16
Study 10705056 — intervention group
Group type: COMPARATOR
Intervention: No anti-staphylococcal treatment (Control)
Number of subjects: 16
Study 10705056 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusidic acid treatment
Number of subjects: 16
Study 9376241 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient controlled analgesia (PCA)
Number of subjects: 30
Study 9376241 — intervention group
Group type: COMPARATOR
Intervention: Conventional intravenous analgesia
Number of subjects: 30
Study 8443851 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 120, 160, 200, or 240 micrograms.kg‐1
Number of subjects: 100
Study 8443851 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium cumulative dose-response
Number of subjects: 100
Study 8443851 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium administration
Number of subjects: 100
Study 3021638 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress inoculation training
Number of subjects: 54
Study 3021638 — intervention group
Group type: COMPARATOR
Intervention: Placebo/information training
Number of subjects: 54
Study 30321440 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosensory therapy (Havening)
Number of subjects: 41
Study 30321440 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychosensory therapy)
Number of subjects: 41
Study 27194308 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation at 2000 IU
Number of subjects: 208
Study 27194308 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation at 4000 IU
Number of subjects: 208
Study 27194308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 27194308 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (both doses)
Number of subjects: 208
Study 24436454 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles vaccine at 4.5 months
Number of subjects: 6417
Study 22974788 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (ACE inhibitor) for 6 weeks
Number of subjects: 250
Study 22974788 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal healthy controls)
Number of subjects: 250
Study 18998329 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids therapy (beclomethasone dipropionate or fluticasone propionate)
Number of subjects: 109
Study 18998329 — intervention group
Group type: COMPARATOR
Intervention: Montelukast or cromones (Control)
Number of subjects: 109
Study 15738024 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics effective against Chlamydia (excluded from analysis)
Number of subjects: 140
Study 15738024 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group of women not receiving antibiotics)
Number of subjects: 140
Study 12875359 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10642678 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ivermectin (200 microg/kg body weight)
Number of subjects: 85
Study 10642678 — intervention group
Group type: COMPARATOR
Intervention: Topical permethrin cream (5%)
Number of subjects: 85
Study 8839911 — intervention group
Group type: EXPERIMENTAL
Intervention: EO9 12 mg/m2 weekly (arm A)
Number of subjects: 38
Study 8839911 — intervention group
Group type: EXPERIMENTAL
Intervention: EO9 22 mg/m2 every three weeks (arm B)
Number of subjects: 38
Study 31251889 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (n=16) cycled 30 min/day, 3 days/week for 4 weeks at 80% heart rate reserve.
Number of subjects: 28
Study 31251889 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=12) with no training intervention.
Number of subjects: 28
Study 31251889 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (n=16) and Control group (n=12) both assessed for SS‐FMD.
Number of subjects: 28
Study 29231263 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-stabilized ABBM (test group)
Number of subjects: 60
Study 29231263 — intervention group
Group type: COMPARATOR
Intervention: ABBM + autogenous bone (control group)
Number of subjects: 60
Study 26778544 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PJ) 200 mL/d for 21 days
Number of subjects: 31
Study 26778544 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice diluted 1:1 with water (PJD) 200 mL/d for 21 days
Number of subjects: 31
Study 26778544 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 31
Study 24266855 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose cyclosporine (rCsA) with sirolimus and corticosteroids
Number of subjects: 420
Study 24266855 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cyclosporine (sCsA) with sirolimus and corticosteroids
Number of subjects: 420
Study 22908696 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient powder (containing iron, folic acid, vitamin C, and zinc)
Number of subjects: 478
Study 22908696 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid tablets
Number of subjects: 478
Study 22908696 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient powder
Number of subjects: 478
Study 22908696 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 478
Study 18373134 — intervention group
Group type: EXPERIMENTAL
Intervention: EMR‐facilitated disease management in System A
Number of subjects: 12675
Study 18373134 — intervention group
Group type: COMPARATOR
Intervention: Patient empowerment interventions in System B
Number of subjects: 12675
Study 16332466 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Intensive Education Programme (MIEP)
Number of subjects: 99
Study 14568122 — intervention group
Group type: EXPERIMENTAL
Intervention: Active neuromuscular stimulation for 5 seconds
Number of subjects: 26
Study 14568122 — intervention group
Group type: EXPERIMENTAL
Intervention: Active neuromuscular stimulation for 10 seconds
Number of subjects: 26
Study 14568122 — intervention group
Group type: COMPARATOR
Intervention: 0 seconds active neuromuscular stimulation (control group)
Number of subjects: 26
Study 10632414 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (0.625 mg)
Number of subjects: 30
Study 10632414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9096964 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and glyburide (1.25-2.5 mg/day)
Number of subjects: 35
Study 9096964 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 35
Study 8237836 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1200
Study 8237836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study 3516511 — intervention group
Group type: EXPERIMENTAL
Intervention: muzolimine, 20 mg/day
Number of subjects: 0
Study 3516511 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide, 50 mg/day and amiloride, 5 mg/day
Number of subjects: 0
Study 30304013 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release (ER) onapristone 50 mg BID
Number of subjects: 52
Study 30304013 — intervention group
Group type: COMPARATOR
Intervention: Immediate release 100 mg QD
Number of subjects: 52
Study 26489776 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic exercise regimen (individually tailored, for 20-30 min at least five times per week)
Number of subjects: 131
Study 26489776 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 131
Study 24387919 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A - scan delay of 65 s after starting contrast injection over 30 s
Number of subjects: 142
Study 24387919 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B - scan delay of 105 s after starting contrast injection over 70 s
Number of subjects: 142
Study 24387919 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol C - scan delay of 145 s after starting contrast injection over 110 s
Number of subjects: 142
Study 22705422 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric energy group (50%-90% of REEm, En-low)
Number of subjects: 33
Study 22705422 — intervention group
Group type: COMPARATOR
Intervention: General energy group (90%-130% of REEm, En-gen)
Number of subjects: 33
Study 22705422 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured REE (REEm)
Number of subjects: 33
Study 22705422 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with APACHE II score
Number of subjects: 33
Study 20178531 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection with acetic acid and cryotherapy
Number of subjects: 0
Study 18821954 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet with basic first aid message regarding tooth avulsion
Number of subjects: 150
Study 18821954 — intervention group
Group type: COMPARATOR
Intervention: Control group (no leaflet)
Number of subjects: 150
Study 16567931 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (adjusted-dose, INR 1.4-2.8)
Number of subjects: 0
Study 16567931 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (325 mg/day)
Number of subjects: 0
Study 12587093 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTI therapy
Number of subjects: 26
Study 12587093 — intervention group
Group type: COMPARATOR
Intervention: Control (treatment-naive)
Number of subjects: 26
Study 10879578 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatment (4 sessions of relaxation and stimulus control)
Number of subjects: 0
Study 10879578 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 0
Study 8792889 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml of bupivacaine 2.5 mg/ml with 3 mg of morphine (Group I)
Number of subjects: 107
Study 8792889 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml of bupivacaine 2.5 mg/ml (Group II)
Number of subjects: 107
Study 8792889 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml isotonic saline with 3 mg morphine (Group III)
Number of subjects: 107
Study 8792889 — intervention group
Group type: COMPARATOR
Intervention: 20 ml of isotonic saline (placebo, Group IV)
Number of subjects: 107
Study 1627201 — intervention group
Group type: EXPERIMENTAL
Intervention: sertaconazole 1% cream
Number of subjects: 20
Study 1627201 — intervention group
Group type: EXPERIMENTAL
Intervention: sertaconazole 2% cream
Number of subjects: 20
Study 6148873 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 38
Study 6148873 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 38
Study 6148873 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 38
Study 6148873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 29602735 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard adjuvant chemotherapy
Number of subjects: 145
Study 29602735 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 145
Study 26976697 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically supported rapid maxillary expansion (SRME)
Number of subjects: 32
Study 26976697 — intervention group
Group type: COMPARATOR
Intervention: Le Fort I osteotomy (LFIO)
Number of subjects: 32
Study 26976697 — intervention group
Group type: COMPARATOR
Intervention: Comparison of SRME and LFIO
Number of subjects: 32
Study 24730623 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard phacoaspiration with PPC and intracameral triamcinolone (Group A)
Number of subjects: 20
Study 24730623 — intervention group
Group type: COMPARATOR
Intervention: No triamcinolone used (Group B)
Number of subjects: 20
Study 23818408 — intervention group
Group type: EXPERIMENTAL
Intervention: Local vibration stimulus training programme
Number of subjects: 31
Study 23818408 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 31
Study 20093373 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced gamma activity at 62 Hz
Number of subjects: 0
Study 20093373 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced gamma activity at 44 Hz
Number of subjects: 0
Study 18823217 — intervention group
Group type: COMPARATOR
Intervention: Etravirine 100 mg after a fasted state
Number of subjects: 24